vs
Side-by-side financial comparison of Bank First Corp (BFC) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $44.9M, roughly 1.9× Bank First Corp). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 12.1%). Bank First Corp produced more free cash flow last quarter ($51.0M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 9.1%).
First Horizon Corporation, formerly First Tennessee Bank, is a financial services company, founded in 1864, and based in Memphis, Tennessee. Through its banking subsidiary First Horizon Bank, it provides financial services through locations in 12 states across the Southeast, a region in which it is the fourth largest regional bank.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
BFC vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $86.8M |
| Net Profit | $18.4M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 51.0% | -84.7% |
| Net Margin | 45.8% | — |
| Revenue YoY | 12.1% | 17.7% |
| Net Profit YoY | 4.8% | — |
| EPS (diluted) | $1.87 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $86.8M | ||
| Q3 25 | $44.2M | $67.5M | ||
| Q2 25 | $41.6M | $60.0M | ||
| Q1 25 | $43.1M | $49.3M | ||
| Q4 24 | $40.1M | $73.7M | ||
| Q3 24 | $40.8M | $58.6M | ||
| Q2 24 | $38.9M | $31.1M | ||
| Q1 24 | $37.7M | $715.0K |
| Q4 25 | $18.4M | — | ||
| Q3 25 | $18.0M | $-91.3M | ||
| Q2 25 | $16.9M | $-111.7M | ||
| Q1 25 | $18.2M | $-116.2M | ||
| Q4 24 | $17.5M | — | ||
| Q3 24 | $16.6M | $-83.5M | ||
| Q2 24 | $16.1M | $-97.1M | ||
| Q1 24 | $15.4M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 51.0% | -84.7% | ||
| Q3 25 | 50.8% | -140.7% | ||
| Q2 25 | 49.7% | -189.8% | ||
| Q1 25 | 51.3% | -245.8% | ||
| Q4 24 | 54.4% | -117.5% | ||
| Q3 24 | 50.7% | -152.1% | ||
| Q2 24 | 51.0% | -327.6% | ||
| Q1 24 | 45.6% | -16464.6% |
| Q4 25 | 45.8% | — | ||
| Q3 25 | 40.7% | -135.3% | ||
| Q2 25 | 40.5% | -186.2% | ||
| Q1 25 | 42.3% | -235.5% | ||
| Q4 24 | 49.3% | — | ||
| Q3 24 | 40.6% | -142.7% | ||
| Q2 24 | 41.3% | -312.2% | ||
| Q1 24 | 40.8% | -15800.8% |
| Q4 25 | $1.87 | — | ||
| Q3 25 | $1.83 | — | ||
| Q2 25 | $1.71 | $-0.33 | ||
| Q1 25 | $1.82 | $-0.36 | ||
| Q4 24 | $1.75 | $-0.24 | ||
| Q3 24 | $1.65 | $-0.28 | ||
| Q2 24 | $1.59 | $-0.34 | ||
| Q1 24 | $1.51 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $243.2M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $643.8M | $698.6M |
| Total Assets | $4.5B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $243.2M | $297.0M | ||
| Q3 25 | $126.2M | $300.8M | ||
| Q2 25 | $120.3M | $301.2M | ||
| Q1 25 | $300.9M | $359.7M | ||
| Q4 24 | $261.3M | $323.8M | ||
| Q3 24 | $204.4M | $397.5M | ||
| Q2 24 | $99.0M | $412.5M | ||
| Q1 24 | $83.4M | $356.2M |
| Q4 25 | $643.8M | $698.6M | ||
| Q3 25 | $628.1M | $702.3M | ||
| Q2 25 | $612.3M | $698.5M | ||
| Q1 25 | $648.4M | $767.9M | ||
| Q4 24 | $639.7M | $710.4M | ||
| Q3 24 | $628.9M | $773.5M | ||
| Q2 24 | $614.6M | $768.5M | ||
| Q1 24 | $609.3M | $680.0M |
| Q4 25 | $4.5B | $913.2M | ||
| Q3 25 | $4.4B | $904.9M | ||
| Q2 25 | $4.4B | $907.4M | ||
| Q1 25 | $4.5B | $966.7M | ||
| Q4 24 | $4.5B | $910.4M | ||
| Q3 24 | $4.3B | $991.1M | ||
| Q2 24 | $4.1B | $964.3M | ||
| Q1 24 | $4.1B | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $62.5M | $-52.6M |
| Free Cash FlowOCF − Capex | $51.0M | $-61.9M |
| FCF MarginFCF / Revenue | 113.6% | -71.3% |
| Capex IntensityCapex / Revenue | 25.5% | 10.7% |
| Cash ConversionOCF / Net Profit | 3.40× | — |
| TTM Free Cash FlowTrailing 4 quarters | $75.8M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $62.5M | $-52.6M | ||
| Q3 25 | $15.5M | $-78.7M | ||
| Q2 25 | $11.9M | $-67.4M | ||
| Q1 25 | $6.2M | $-103.7M | ||
| Q4 24 | $65.8M | $-73.3M | ||
| Q3 24 | $18.8M | $-59.0M | ||
| Q2 24 | $14.9M | $-98.4M | ||
| Q1 24 | $1.3M | $-122.3M |
| Q4 25 | $51.0M | $-61.9M | ||
| Q3 25 | $12.5M | $-89.5M | ||
| Q2 25 | $8.2M | $-74.9M | ||
| Q1 25 | $4.0M | $-109.9M | ||
| Q4 24 | $58.6M | $-77.5M | ||
| Q3 24 | $16.9M | $-61.3M | ||
| Q2 24 | $13.7M | $-98.9M | ||
| Q1 24 | $551.0K | $-126.5M |
| Q4 25 | 113.6% | -71.3% | ||
| Q3 25 | 28.2% | -132.7% | ||
| Q2 25 | 19.8% | -124.9% | ||
| Q1 25 | 9.3% | -222.8% | ||
| Q4 24 | 146.3% | -105.1% | ||
| Q3 24 | 41.5% | -104.6% | ||
| Q2 24 | 35.3% | -317.9% | ||
| Q1 24 | 1.5% | -17685.3% |
| Q4 25 | 25.5% | 10.7% | ||
| Q3 25 | 6.7% | 16.1% | ||
| Q2 25 | 8.7% | 12.4% | ||
| Q1 25 | 5.0% | 12.6% | ||
| Q4 24 | 18.0% | 5.7% | ||
| Q3 24 | 4.5% | 3.9% | ||
| Q2 24 | 3.1% | 1.4% | ||
| Q1 24 | 2.1% | 583.4% |
| Q4 25 | 3.40× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 3.75× | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 0.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFC
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
